NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRYPTYR (acoltremon) is an ophthalmic solution approved by the FDA on May 28, 2025, for use in eye care. The exact indication and mechanism of action are not disclosed in available data, but the formulation represents a novel therapeutic approach in ophthalmology. As a recently approved NDA product, it enters a specialized therapeutic area with distinct commercial dynamics.
Growth16.1 years to LOE
As a newly launched product in growth phase with no identified direct competitors, the commercial team will focus on market penetration and prescriber awareness building, likely supporting a lean but expanding field organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain
Started Oct 2026
28 enrolled
Ocular PainDry Eye
Career Relevance
TRYPTYR represents a career opportunity in a newly launched, growth-stage ophthalmic product with extended patent protection and no direct competition, allowing early team members to establish market presence and prescriber relationships. The specialized ophthalmic route and Alcon's strong footprint in this therapeutic area create a focused, stable career platform with clear commercial visibility through 2042.
Brand Manager
Worked on TRYPTYR at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.